

Special Issue

Foot and Mouth Disease Virus Vaccines Developments

Message from the Guest Editors

Foot-and-mouth disease virus (FMDV) is a highly contagious viral infection of cloven-hoofed animals. FMDV outbreaks cause significant and devastating economic impacts worldwide. The most effective and widely accepted way to respond to outbreaks is through the use of chemically inactivated vaccination of domestic livestock. However, these inactivated vaccines are slow-acting and do not always permit a distinction between infected and vaccinated animals. Therefore, it is essential to develop new rapid vaccines and control strategies that could confer early protection and rapidly stop disease spread. This Special Issue will cover the FMDV determinant of replication and pathogenesis and how this information facilitates next-generation FMDV vaccine and biotherapeutic developments. We particularly encourage the submission of manuscripts focused on improved control strategies addressing important gaps in the current inactivated FMDV vaccine including, but not limited to, duration of immunity, cross-reactivity, correlates of protection, early protection, antigen load, immunization responses, and safer marker vaccines.

Guest Editors

Dr. Katherine Pflaum

Foreign Animal Disease Research Unit, United States Department of Agriculture, Agricultural Research Service, Plum Island Animal Disease Center, Greenport, NY 11944, USA

Dr. Wilna Vosloo

Australian Centre for Disease Preparedness, CSIRO-Health & Biosecurity, 5 Portarlington Road, Geelong, VIC 3220, Australia

Deadline for manuscript submissions

closed (16 June 2023)



Vaccines

an Open Access Journal
by MDPI

Impact Factor 3.4
CiteScore 7.7
Indexed in PubMed



mdpi.com/si/147306

Vaccines
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
vaccines@mdpi.com

[mdpi.com/journal/
vaccines](https://mdpi.com/journal/vaccines)





Vaccines

an Open Access Journal
by MDPI

Impact Factor 3.4
CiteScore 7.7
Indexed in PubMed



[mdpi.com/journal/
vaccines](https://mdpi.com/journal/vaccines)



About the Journal

Message from the Editor-in-Chief

Vaccines (ISSN 2076-393X), founded in 2013, now has a firm history of publishing peer-reviewed, state-of-the-art research papers on vaccines and vaccination in the broadest sense. Areas covered include, but are not limited to, novel and emerging vaccine technologies, building on in-depth knowledge of what constitutes a protective immune response. These can be new vaccines for old diseases, or old vaccines for new diseases. Vaccines against cancer and autoimmune diseases explicitly are also within the scope of the journal. Because public opinion and even government policies towards vaccines and vaccination have changed, vaccine policy and public health issues are major concerns. Climate change will also have an impact on the spread of infectious diseases, and thus also on vaccine and vaccination policies worldwide.

Editor-in-Chief

Prof. Dr. Ger Rijkers

Department of Health, Cognition and Behavior, University College
Roosevelt, 4331 CB Middelburg, The Netherlands

Author Benefits

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

Journal Rank:

JCR - Q2 (Medicine, Research and Experimental) /
CiteScore - Q1 (Infectious Diseases)

Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 18.1 days after submission; acceptance to publication is undertaken in 2.8 days (median values for papers published in this journal in the second half of 2025).